Karthik Gujja
Cardiovascular Disease · Westbury, NYNPI 1780843086
Payments from drug & device makers
Across 785 payments — averaging $112.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$45K
- Abbott$37K
- Cagent Vascular Inc$1K
- Cardiovascular Systems Inc.$1K
- Shockwave Medical, Inc$918
- Biotronik Inc.$725
- plus $3K from 23 others
What the payments were for
- Consulting fees$25,70029%
- Speaking & faculty fees$34,05039%
- Travel & lodging$8821%
- Food & beverage$27,69031%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 491 | $44,627 |
| Abbott | 103 | $36,849 |
| Cagent Vascular Inc | 22 | $1,219 |
| Cardiovascular Systems Inc. | 26 | $1,148 |
| Shockwave Medical, Inc | 22 | $918 |
| Biotronik Inc. | 23 | $725 |
| Bard Peripheral Vascular, Inc. | 7 | $515 |
| Boston Scientific | 10 | $404 |
| Philips North America LLC | 7 | $268 |
| Tactile Systems Technology Inc | 10 | $225 |
| Novartis | 16 | $219 |
| Smith+Nephew | 4 | $210 |
| Cook Medical LLC | 10 | $203 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 10 | $190 |
| Stryker | 2 | $102 |
| W. L. Gore & Associates, Inc. | 2 | $90 |
| Johnson & Johnson | 4 | $83 |
| Recor Medical Inc | 2 | $75 |
| BD | 1 | $62 |
| Angiodynamics, Inc. | 3 | $54 |
| Boehringer Ingelheim | 2 | $38 |
| Cardiva Medical, Inc. | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Heartflow, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Renalytix AI, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnilink Elite vascular stent system$21,450
- VenaSeal$12,733
- HawkOne$11,597
- IN.PACT Admiral$5,700
- ESPRIT$5,580
- Supera peripheral stent system$3,012
- HI-TORQUE COMMAND$3,000
- XIENCE SIERRA$1,500
- ClosureFast$778
- TurboHawk$557
- Serrantor$467
- SUPERA$416
- Peripheral Orbital Atherectomy System$341
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$308
- Perclose ProGlide suture mediated closure system$285
- Pulsar-18 T3$266
- Micra$162
- GENERAL - THERAPIES$145
- JETI$135
- Crosser iQ$121
How this compares
$88,375 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 212 | $205,173 |
| EliquisApixaban | 150 | $139,265 |
| BrilintaTicagrelor | 76 | $65,024 |
| EntrestoSacubitril/Valsartan | 32 | $35,670 |
| JardianceEmpagliflozin | 12 | $14,509 |
| FarxigaDapagliflozin Propanediol | 13 | $13,707 |
| ClopidogrelClopidogrel Bisulfate | 1,199 | $10,350 |
| Cephalexin | 1,095 | $4,764 |
| Metoprolol Succinate | 284 | $3,726 |
| Ranolazine ErRanolazine | 61 | $3,134 |
| Atorvastatin Calcium | 290 | $2,895 |
| Cilostazol | 189 | $2,740 |
| Nifedipine ErNifedipine | 94 | $2,442 |
| Rosuvastatin Calcium | 123 | $2,187 |
| Losartan Potassium | 98 | $932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $83 | $205,173212 claims |
| NovartisEntresto | $219 | $35,67032 claims |
| Boehringer IngelheimJardiance | $38 | $14,50912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Westbury
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.